Answers are grounded in this paper and cite their sources.
These results suggest that an NK cell line could be the basis for an off-the-shelf TCR-based cancer immunotherapy solution. FUND: This work was supported by the Research Council of Norway (#254817), South-Eastern Norway Regional Health Authority (#14/00500-79), by OUS-Radiumhospitalet (Gene Therapy program) and the department of Oncology at the University of Lausanne.
No takes yet. Share an insight, caveat, or question.
Mensali et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: